Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05502315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Study acronym: CANOPY
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 12, 2026 → Oct 12, 2026
See other at-risk trials from Rana McKay, MD

Record History

  1. Primary completion pushed from Jul 12, 2026 to Oct 12, 2026 Completion pushed from Jul 12, 2027 to Oct 12, 2027v24 Show 1 more changeShow less
    • Completion pushed from Jul 12, 2027 to Oct 12, 2027
  2. Re-verified, no change to tracked fieldsv23
  3. Trial status changed: Recruiting → Active, Not Recruiting Primary completion pushed from Apr 12, 2026 to Jul 12, 2026 · Completion pushed from Apr 12, 2027 to Jul 12, 2027 · Site details revised at 4 of 4 sitesv22 Show 3 more changesShow less
    • Primary completion pushed from Apr 12, 2026 to Jul 12, 2026
    • Completion pushed from Apr 12, 2027 to Jul 12, 2027
    • Site details revised at 4 of 4 sites
  4. 2 versions Re-verified since Nov 4, 2025, no change to tracked fieldsv20-v21
  5. Site contacts updated at 4 of 4 sitesv19
Show 17 earlier versionsHide 17 earlier versions
  1. Enrollment target: 50 to 47 Eligibility criteria expanded, about 19 words · Site contacts updated at 4 of 4 sitesv18 Show 2 more changesShow less
    • Eligibility criteria expanded, about 19 words
    • Site contacts updated at 4 of 4 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 3 to 4v17
  3. Eligibility criteria expanded, about 10 wordsv16 See this version in full on ClinicalTrials.gov ↗
  4. Primary completion date: May 12, 2024 to Apr 12, 2026 Completion date: Oct 12, 2024 to Apr 12, 2027v15 Show 1 more changeShow less
    • Completion date: Oct 12, 2024 to Apr 12, 2027
  5. Primary completion date: Feb 12, 2024 to May 12, 2024v14
  6. Primary completion date: Dec 12, 2023 to Feb 12, 2024v13
  7. Primary completion date: Oct 12, 2023 to Dec 12, 2023v12
  8. Study sites: 2 to 3v11
  9. Eligibility criteria shortened, about 20 wordsv10 See this version in full on ClinicalTrials.gov ↗
  10. Site contacts updated at 1 of 2 sitesv9
  11. Study sites: 1 to 2v8
  12. Eligibility criteria expanded, about 1 wordv7 See this version in full on ClinicalTrials.gov ↗
  13. 2 versions Re-verified since Feb 27, 2023, no change to tracked fieldsv5-v6
  14. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Apr 2023 to Feb 2, 2023 · Eligibility criteria expanded, about 461 wordsv4 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2023 to Feb 2, 2023
    • Eligibility criteria expanded, about 461 words

    See this version in full on ClinicalTrials.gov ↗

  15. Re-verified, no change to tracked fieldsv3
  16. Primary completion date: Apr 12, 2023 to Oct 12, 2023 Start date: Oct 2022 to Apr 2023 · Completion date: Apr 12, 2024 to Oct 12, 2024v2 Show 2 more changesShow less
    • Start date: Oct 2022 to Apr 2023
    • Completion date: Apr 12, 2024 to Oct 12, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rana McKay, MD
2 trials monitored
See 1 trial at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Trial Details
NCT Number NCT05502315
Lead Sponsor Rana McKay, MD
Collaborators: Exelixis, Bristol-Myers Squibb
Conditions Castration-resistant Prostate Cancer, Metastatic Cancer
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov